Business Context and Reporting Period
This Form 8-K Current Report was filed by Alnylam Pharmaceuticals, Inc. on September 29, 2004. The report addresses a corporate governance event regarding the board of directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a disclosure of personnel changes and contains no financial data.
Material Changes
The material change disclosed is the resignation of Christoph H. Westphal, M.D., Ph.D., from the board of directors. His resignation is effective October 14, 2004.
Guidance, Outlook, and Risks
The filing does not contain guidance, outlook, management commentary on operations, risks, contingencies, or unusual items beyond the director's departure.
Key Facts for Investors
- Christoph H. Westphal, M.D., Ph.D., is resigning from the Alnylam board of directors.
- The resignation becomes effective on October 14, 2004.
- The report was signed by John M. Maraganore, Ph.D., President and Chief Executive Officer, on October 4, 2004.